UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
Completed
- Conditions
- Epilepsy
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 180
- Registration Number
- NCT00302991
Mucosal Healing Study in Crohn's Disease (CD)
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Certolizumab pegol
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 89
- Registration Number
- NCT00297648
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 82
- Registration Number
- NCT00296192
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00292227
- Locations
- 🇿🇦
Farmovs-Parexel (Pty) Ltd, Bloemfontein, South Africa
🇿🇦Qdot, a division of Parexel International DA (Pty) Ltd., George, South Africa
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
Phase 2
Completed
- Conditions
- RhinitisAllergicSeasonal
- Interventions
- Drug: Placebo dropsDrug: Placebo tablets matching to cetirizine
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 551
- Registration Number
- NCT00291642
Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 130
- Registration Number
- NCT00291655
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Certolizumab PegolOther: Placebo
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 94
- Registration Number
- NCT00291668
A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Phase 3
Completed
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00275236
- Locations
- 🇩🇪
Schwarz BioSciences, Monheim, Germany
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Phase 4
Completed
- Conditions
- Panic DisorderGeneralized Anxiety Disorder
- Interventions
- Drug: SSRI/SNRI
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 418
- Registration Number
- NCT00266409
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
CUTE (Chronic Urticaria Treatment Evaluation)
Phase 4
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 886
- Registration Number
- NCT00264303
© Copyright 2025. All Rights Reserved by MedPath